Johnson & Johnson (JNJ)
Last Price$163.3(0.2%)
Market Cap$393.0B
JNJ Rating
JNJ Quality rating performance
JNJ Intrinsic Value
Key Highlights:
As of Mar 24, 2025 JNJ Relative Value is $172.3, which is undervalued by 5.5%, compared to current share price of $163.3.
As of Mar 24, 2025 JNJ DCF Value is $221.5, which is undervalued by 35.7%, compared to current share price of $163.3.
JNJ Share Price History
1W 0.3%
1M (0.3%)
6M 1.9%
YTD 6.1%
1Y 8.6%
3Y 1.8%
5Y 57.6%
10Y 111.3%
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!
JNJ Stock Metrics
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
$393.0B
$405.1B
$88.8B
$18.1B
Shares Outstanding
2,407M
Employees
138K
Growth (CAGR)
1.6%
(0.56%)
(1.9%)
81.27%
Profitability
69.1%
24.8%
15.8%
27.3%
20.3%
128.4%
Intrinsic Value
$196.2 (20.2% undervalued)
$220.5
$172.0
$238.2
$507.3
71.3%
Return on Capital
Financial Health
$12.1B
0.7x
29.2x
51.2%
Dividends
8.4%
3.0%
65.5%
Feb 18, 2025
Earnings
Jul 15, 2025
BEAT by 0.4%
BEAT by 2.5%
(21.2%)
10 Beat & null Miss
JNJ Stock Financials
JNJ Income Statement Metrics
Annual
Quarterly
LTM
JNJ Cash Flow Statement Metrics
Annual
Quarterly
LTM
Operating Cash Flow (OCF)
$24.3B +6.5% YoY
Capital Expenditure (CAPEX)
($4,424.0M) +36.6% YoY
Free Cash Flow (FCF)
$19.8B -1.0% YoY
JNJ Income Statement Overview
Annual
Quarterly
LTM
Jan'16
Jan'17
Dec'17
Dec'18
Dec'19
Jan'21
Jan'22
Jan'23
Dec'23
Dec'24
$88.8B 4.3% YoY
Cost of revenue
$27.5B 3.5% YoY
Pre-tax income
$16.7B 10.8% YoY
18.8% margin
JNJ Balance Sheet Overview
Annual
Quarterly
LTM
Jan'16
Jan'17
Dec'17
Dec'18
Dec'19
Jan'21
Jan'22
Jan'23
Dec'23
Dec'24
Assets
Liabilities
Total assets
$180.1B
Current assets ($55.9B, 31.0% of total)
$24.5B (13.6%)
$18.9B (10.5%)
Other current assets
$12.4B (6.9%)
Non-current assets ($124.2B, 69.0% of total)
$0.0 (0.0%)
$21.6B (12.0%)
$37.6B (20.9%)
Other non-current assets
$65.0B (36.1%)
Financial position
$12.1B
Cash & Short-term
Investments
Total Debt
JNJ Stock Ratios
Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
JNJ Earnings Surprises
Crunching data... Almost there!
JNJ Dividends
JNJ Dividend Yield
Crunching data... Almost there!
JNJ Dividend Per Share
3Y
10Y
30Y
Annual
Quarterly
LTM
Competing with JNJ
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$393.0B | 6.0 | $196.2 20.2% undervalued | 8.6% | $88.8B | $18.1B | 4.3% | 20.3% | 69.1% | 15.7% | 51.2% | |
$781.6B | 7.0 | $225.0 74.0% overvalued | 12.6% | $45.0B | $510.8M | 32.0% | 1.1% | 81.6% | 40.7% | 235.7% | |
$369.2B | 6.0 | $300.2 43.5% undervalued | 21.4% | $56.3B | $17.8B | 3.7% | 31.7% | 73.6% | 8.3% | 1,996.0% | |
$335.5B | 7.1 | $71.1 5.6% overvalued | (41.5%) | DKK 290.4B | DKK 70.0B | 25.0% | 24.1% | 84.7% | 35.5% | 71.6% | |
$234.6B | 7.5 | $112.5 21.8% undervalued | (24.8%) | $64.2B | $18.1B | 6.7% | 28.2% | 80.8% | 26.5% | 80.0% | |
$230.3B | 6.8 | $69.8 5.7% overvalued | 14.8% | $54.1B | $7,275.0M | 18.0% | 13.5% | 81.1% | 15.4% | 73.7% | |
$220.7B | 6.6 | $150.6 35.5% undervalued | 16.0% | $51.1B | $13.8B | 0.1% | 27.0% | 74.7% | 17.7% | 70.8% | |
$169.9B | 5.9 | $448.1 42.5% undervalued | 15.4% | $33.4B | $10.4B | 18.6% | 31.1% | 61.5% | 11.9% | 1,022.6% | |
$148.1B | 6.1 | $25.4 2.8% overvalued | 1.3% | $63.6B | $9,835.0M | 8.8% | 15.5% | 65.6% | 9.0% | 71.9% | |
$140.1B | 4.8 | $90.0 60.9% undervalued | 16.6% | €44.3B | (€504.0M) | (22.5%) | (1.1%) | 70.2% | 7.4% | 23.0% | |
$133.1B | 6.1 | $91.5 14.2% overvalued | 51.4% | $28.7B | $10.5B | 6.0% | 36.4% | 78.3% | 20.1% | 138.8% |
FAQ
What is Johnson & Johnson (JNJ) stock rating?
As of today, Johnson & Johnson has a stock rating of 6 (out of 10), which is considered Good.
is Johnson & Johnson (JNJ) a good stock to buy?
As of today, Johnson & Johnson has a Good stock rating, which is 20.2% undervalued. According to Value Sense backtesting, stocks with similar profile tend to outperform the market by 3.2%.